With all the uncertainty of COVID-19, we hope you are safe and in good health. Ozgene is still here to meet your research needs.

A mouse well travelled

A mouse well travelled

A mouse well travelled

In this issue

– Feature
– Latest publications
– Updates


Global Ozgene teamA mouse well travelled

It was recently brought to our attention that a mouse model generated by Ozgene has become very useful in the area of cancer research. This particular model has been used to study melanomas, lung cancer, ovarian tumorigenesis, ductal hyperplasia and adenocarcinoma on two continents.

The Pik3ca (lat-1047R) mouse, originally developed by Ozgene for Dr Wayne Phillips and recently utilized by Dr Martin McMahon, has been used in a range of cancer research that has led to five scientific publications so far.

Dr Phillips is the head of the Surgical Oncology Research (Phillips) Laboratory at the Peter MacCallum Cancer Centre in Australia. His main focus and interest of study is on the role of the phosphoinositide 3-kinase (PI3K) signalling pathway in cancer. The novel mouse model created for his research has proved useful not only for himself, but for others around the world studying cancer, particularly Dr McMahon.

“The Pik3ca(lat-1047R) mouse, generated by Ozgene for Dr. Wayne Phillips, is turning out to be a very useful addition to our tools for studying PI3′-kinase signaling alone and in concert with other pathways. In my opinion, it is superior to the more conventional transgenic mice used for similar purposes.”

-Dr Martin McMahon

Dr McMahon is the Director of Professional Education and Co-Leader of the Developmental Therapeutics Program at the UCSF Helen Diller Family Comprehensive Cancer Center. The novel Pik3ca mouse model was utilized by Dr McMahon in his research on the role of RAS-regulated signal transduction pathways in the aberrant behaviour of melanoma, thyroid, pancreas and lung cancer.

To read more about the research conducted with the Pik3ca (lat-1047R) mouse, please visit the Phillips Laboratory website, McMahon Laboratory website and read the publications below.

To find out more about Ozgene mouse models, visit the Ozgene website.


Our customers publish more often

The team at Ozgene has over two decades of experience creating customised knockout and knockin mice for pivotal medical research globally. Over 200 scientific publications are based on research using Ozgene mice. All of the following publications have stemmed from research using the Pik3ca (lat-1047R) mouse developed by Ozgene for Dr Wayne Phillips.

Biochem J. 2014 Mar 1.
Physiological expression of the PI3K-activating mutation Pik3caH1047R combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.
Hare LM, Phesse TJ, Waring PM1, Montgomery KG2, Kinross KM, Mills K2, Roh V2, Heath JK, Ramsay RG, Ernst M, Phillips WA. University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. [read]

J Clin Invest. 2013 Dec 2.
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. [read]

Cancer Res. 2013 Nov 1.
Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. and Peter MacCallum Cancer Centre, University of Melbourne, VIC, Australia. [read]

PLoS One. 2012 May 30.
Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. [read]

J Clin Invest. 2012 Feb 1.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. [read]

Go to papers


Einstein mouse

Geneoz VMS

We make it easy for you to know the location, genotype, history, project allocation, health status and husbandry requirements of each and every animal in your Vivarium. Contact us for a free trial of the Geneoz Vivarium Management System!

Idea mouse

Did you know?

Ozgene is the innovator in C57BL/6 strain. Before founding Ozgene in 1999, Dr Frank Koentgen (CEO) & Dr Gabi Suess (CSO) were the first to generate and publish C57BL/6 KO mice in 1993. Go to our website to see the complete Ozgene history.

Microscope mouse

What is your GOI?

Let us know your gene of interest and what kind of genetic modification you are interested in. Ozgene will provide a completely obligation free scientific assessment and quote for your project. Contact us for a confidential discussion.